Autonomix Medical(US:AMIX) Globenewswire·2025-12-30 13:30Core Insights - Autonomix Medical, Inc. has been granted a new European patent (EP4230133) that enhances its strategic position in the nerve-sensing and modulation market, which is valued in the multi-billion-dollar range [1][2] - The patent covers systems and methods for precise treatment of cardiac tissues, including feedback-driven neuromodulation and denervation, which could transform treatment in cardiology and related fields [1][2] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [4] - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, which could significantly improve patient outcomes [4] Technology and Applications - The newly granted patent expands the company's ability to provide precision nerve-targeted therapies for conditions such as hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - Autonomix's technology platform has the potential to address multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [3][5] Market Potential - The patent positions Autonomix to capitalize on high-growth areas in cardiology, potentially reducing complications associated with traditional systemic treatments [2] - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [5]